COUGAR BIOTECHNOLOGY BEGINS PHASE I/II TRIAL FOR CB7630

Cougar Biotechnology has announced that the first patient has been enrolled in the Phase I/II trial of the company's drug CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17, for the treatment of advanced prostate cancer.

The trial is an open label, dose-escalating study to evaluate the safety and efficacy of CB7630 administered daily to patients with chemotherapy-naive hormone refractory prostate cancer with a rising PSA prostate specific antigen despite hormonal therapy.